Effect and Mechanism of Baitouweng Decoction for Large Intestine Damp-heat Syndrome of Ulcerative Colitis

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorThe Second Hospital of Nanjing Medical University

About this trial

Baitouweng Decoction is traditionally used to treat large intestine damp-heat syndrome of ulcerative colitis (UC) by oral administration and rectal enema.The project applicant's invention of transendoscopic entral tubing (TET) has been used in Baitouweng Decoction for the treatment of UC across the whole colon, however, the efficacy have not been reported and the underlying mechanism is still unclear. Compared with oral and rectal enema, Baitouweng Decoction by colon TET can improve the therapeutic effect by increasing the concentration of drugs in the whole colon, which need to be verified. This project will reveal the prescription effect and drug-microbiome interaction mechanism of whole colon repeated administration of Baitouweng Decoction in the treatment of UC through clinical randomized controlled studies, deep intestinal dynamic sampling, integrated analysis of multi-omics and TCM prescription metabolomics studies, and provide key scientific basis for the establishment of a new approach of whole colon repeated administration of TCM and a new strategy for the treatment of UC.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients diagnosed with ulcerative colitis;

The patients are in mild to moderate active stage with Mayo score of 3-8.

Patients with damp-heat syndrome of large intestine according to TCM syndrome differentiation: according to the expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of UC, the main symptoms are diarrhea, mucopurulent and bloody stool, abdominal pain, and tenesmus. Secondary symptoms: anal burning, body heat is not Yang, dry mouth and bitter mouth, short red urine. Tongue pulse: tongue red fur yellow greasy, pulse slippery number. The determination of the above 8 syndromes can be made if there are 2 main symptoms and 1-2 secondary symptoms. The tongue pulse is for reference only.

The patients who can tolerate Baitouweng Decoction;

Disqualifiers

The patients are complicated with other diseases that may cause diarrhea, such as infectious colitis, radiation enteritis, Crohn's disease, etc.

Patients with heart, brain, lung, liver, kidney and other serious diseases;

Patients do not cooperate to complete the clinical trial process;

Other cases considered unsuitable for inclusion.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Baitouweng Tang

    Drug

    Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.

  • Placebo

    Other intervention

    The same volume and color as Baitouweng Decoction.

Treatment groups

144 Participants
are divided into 4 treatment groups
Group A: Colonic TET treatment groupExperimental treatment 1 intervention
Group B: Colonic TET placebo groupPlacebo comparator 1 intervention
Group C: Rectal enema groupActive comparator 1 intervention
Group D: Oral groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

The concentration of fecal calprotecin.

To compare the concentration of fecal calprotecin before and after oral, colonic TET and rectal enema administration.

Time frame
Baseline; Day 15; Day 53

Secondary outcomes

1

The change of Mayo score.

To compare the change of Mayo score before and after oral, colonic TET and rectal enema administration. The Mayo score included the number of bowel movements, blood in the stool, endoscopic findings and overall physician evaluation. The total score was 12 points. The higher the score, the higher the degree of disease activity.

Time frame
Baseline; Day 15; Day 22; Day 53; Day 99.
2

Incidence of Treatment-Emergent Adverse Events

The number of adverse reactions that are associated with Baitouweng Decoction reported by subjects from the start of treatment to the end of follow-up.

Time frame
Day 15; Day 22; Day 53; Day 99.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Second Hospital of Nanjing Medical University

Lead sponsor

Heilongjiang University of Chinese Medicine

Collaborator